GlassScriptPhysician profile
Reham Ghali
NPI 1639618226
$17,131.91
in general payments reported to CMS, 2019-2025
60 companies · $9,467 in 2025
The $9,467 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,407 · 2022: $2,381 · 2023: $1,824 · 2024: $2,053 · 2025: $9,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,873 · Honoraria: $5,375 · Travel and Lodging: $895 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,873.15 |
| Honoraria | $5,375.00 |
| Travel and Lodging | $895.47 |
| Education | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $7,028.77 | 2023-2025 | Symbravo, Sunosi |
| Abbvie INC. | $2,878.05 | 2021-2025 | |
| Ucb, INC. | $664.31 | 2022-2025 | Briviact, Nayzilam, Fintepla |
| Eisai INC. | $587.10 | 2021-2025 | |
| Lundbeck LLC | $517.80 | 2022-2025 | Vyepti |
| Alexion Pharmaceuticals, INC. | $517.68 | 2021-2025 | Ultomiris, Soliris |
| Amgen INC. | $509.81 | 2021-2025 | Uplizna, Aimovig |
| Argenx US, INC. | $381.29 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Impel Pharmaceuticals INC. | $361.96 | 2022-2023 | Trudhesa |
| Pfizer INC. | $340.33 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $263.60 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $231.31 | 2021-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $223.15 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $208.19 | 2022-2024 | Zeposia |
| Biogen, INC. | $194.35 | 2021-2025 | Vumerity, Leqembi, Tysabri |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reham Ghali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.